News Alert

Exelixis, Maker of Expensive Cancer Drugs, Is Latest Manufacturer to Impose 340B Contract Pharmacy Conditions

California-based biopharmaceutical company Exelixis is the 17th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

AstraZeneca and Sanofi Ask 340B ADR Panel to Dismiss Health Centers’ Overcharging Claims

AstraZeneca and Sanofi asked a 340B administrative dispute resolution panel to dismiss NACHC’s claims its members are being overcharged due to the companies’ 340B contract pharmacies policies.

Drug manufacturers AstraZeneca and Sanofi have asked a 340B administrative dispute resolution panel to dismiss the National Association of Community Health Centers’ claims that its members are being overcharged due to the companies’ denied or restricted 340B sales

Read More »

GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs

GlaxoSmithKline is ending voluntary 340B pricing for rural and cancer hospitals on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

In a blow to rural and cancer hospitals, U.K. drug manufacturer GlaxoSmithKline (GSK) is ending voluntary 340B pricing for them on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

Read More »

Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges

e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021.

Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.

Read More »

OptumRx Says Providers Can’t Share 340B Claims Data Without its Consent

OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers.

Pharmacy care services company OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers to satisfy manufacturers’ conditions on 340B pricing.

Please Login

Read More »

Judge’s 340B Statutory Interpretation Was “Exactly Backward,” Lilly Tells Appeals Court

Lilly told a federal appeals court its decision in the drug company's 340B contract pharmacy lawsuit "will have profound consequences for the integrity of the national healthcare system."

A federal district court’s ruling last October that federal law requires drug manufacturers to deliver 340B purchased drugs to contract pharmacies conflicts with two other courts’ conclusions, “upsets the delicate statutory balance Congress struck, and raises serious constitutional

Read More »

340B Report Publisher and CEO: Momentum for 340B Protections Is Growing

340B healthcare providers have turned to the states to address challenges to the drug discount program, 340B Report Publisher and CEO Ted Slafsky says.

Safety net healthcare providers increasingly have turned to the states to address challenges to the 340B program, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

Read More »

PhRMA-funded Study Faults 340B Hospitals’ Financial Aid and Debt Collection Policies

The AHA sharply criticized a new PhRMA-funded study that says many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions."

Many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions, including but not limited to, liens, foreclosures, and civil actions when patients fail to pay bills,” a pharmaceutical-industry funded

Read More »

NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue

An opinion article in the New England Journal of Medicine says overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options. Some HIV/AIDS care providers say high drug prices are the problem, not 340B.

Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last

Read More »

BMS Updates its Conditions on 340B Pricing Involving Contract Pharmacy

BMS updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos.

Drug manufacturer Bristol Myers Squibb (BMS) yesterday updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos, a potential blockbuster product.

Please Login

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report